WHAT IS CLAIMED IS:

1. A method for immunizing an animal against heterologous HIV-1 comprising administering to said animal an immunogen comprising at least one modified HIV-1 envelope protein or fragment thereof, or DNA or virus encoding said at least one modified HIV-1 envelope protein or fragment thereof, or a combination thereof, said modified envelope protein or fragment thereof having a V2 region deletion, wherein said animal exhibits immunity to at least one HIV-1 strain other than that of said immunogen.

2. The method of claim 1 wherein said immunity comprises a humoral response.

3. The method of claim 1 wherein said immunogen comprises a modified HIV-1 envelope protein from a clade-B HIV-1 strain.

4. The method of claim 3 wherein said HIV-strain is SF162.

5. The method of claim 4 wherein said modified HIV-1 envelope protein is SEQ ID No:2 or SEQ ID No:4.

6 8. The method of claim 4 wherein said DNA encoding said at least one modified HIV-1 envelope protein is SEQ ID No:1 or SEQ ID No:3.

7 6. The method of claim 2 wherein said humoral response comprises neutralizing antibodies.

Rule 1.26

8. The method of claim 2 wherein said humoral response comprises protective antibodies.

9. The method of claim 1 wherein said animal is a human.

10. A method for eliciting a heterologous immune response to HIV-1 in an animal comprising immunizing said animal with an immunogen comprising at least one modified HIV-1 envelope protein or fragment thereof, or DNA or virus encoding said at least one modified HIV-1 envelope protein or fragment thereof, or a combination thereof, said modified envelope protein or fragment thereof having a V2 region deletion, wherein said animal exhibits a an envelope-specific immune response to at least one HIV-1 strain other than that of said immunogen.

11. The method of claim 9 wherein said envelope-specific immune response comprises a humoral response.

12. The method of claim 9 wherein said immunogen comprises a modified HIV-1 envelope protein from a clade-B HIV-1 strain.

13. The method of claim 11 wherein said HIV-strain is SF162.

14. The method of claim 12 wherein said modified HIV-1 envelope protein is SEQ ID No:2 or SEQ ID No:4.

15
14. The method of claim 12 wherein said DNA encoding said at least one modified HIV-1 envelope protein is SEQ ID No:1 or SEQ ID No:3.

16
15. The method of claim 10 wherein said humoral response comprises neutralizing antibodies.

17
16. The method of claim 10 wherein said humoral response comprises protective antibodies.

18
17. The method of claim 9 wherein said animal is a human.

19
18. A pharmaceutical composition for immunizing an animal against HIV-1 virus comprising an effective heterologous envelope-specific immune response-eliciting amount of at least one modified HIV-1 envelope protein or fragment thereof, or DNA or virus encoding said at least one modified HIV-1 envelope protein or fragment thereof, or a combination thereof, said modified envelope protein or fragment thereof having a V2 region deletion; and a pharmaceutically-acceptable carrier or excipient.

20
19. The pharmaceutical composition of claim 18 wherein said modified HIV-1 envelope protein is from a clade-B HIV-1 strain.

21
20. The pharmaceutical composition of claim 19 wherein said HIV-1 strain is SF162.

22. ~~21.~~ The pharmaceutical composition of claim 20 wherein said modified HIV-1 envelope protein is SEQ ID No:2 or SEQ ID No:4.

23. ~~22.~~ The pharmaceutical composition of claim 20 wherein said DNA encoding said at least one modified HIV-1 envelope protein is SEQ ID No:1 or SEQ ID No:3.

24. ~~23.~~ A method for assessing whether a compound is capable of generating protective antibodies in an animal against at least one heterologous strain of HIV-1, said animal capable of developing protective antibodies against wild-type HIV-1, said method comprising the steps of immunizing said animal with said compound, depleting said animal of its CD8+ T-lymphocytes, and assessing the presence of protective antibodies in the said animal to at least one heterologous strain of HIV-1.

25. ~~24.~~ The method of claim 23 wherein said depleting is carried out by administering to said animal anti-CD8 monoclonal antibodies.

26. ~~25.~~ The method of claim 23 wherein said compound is an HIV-derived polypeptide or fragment thereof or a DNA or virus encoding said peptide or fragment thereof.

27. ~~26.~~ The method of claim 23 wherein said immunizing is carried out with a DNA vaccine, a protein, or a combination thereof.

28. ~~27.~~ The method of claim 23 wherein said neutralizing antibodies are protective antibodies.